“The American Gateway” — out now

How European pharmaceutical companies enter, price, and win in the United States — a strategic and regulatory field guide.

The mirror image of our inbound work: this is the outbound playbook for European pharma crossing the Atlantic. The US is the world’s largest and most lucrative pharma market — and its rules of entry, pricing and reimbursement look nothing like Europe’s. This field guide maps the whole crossing.

What it covers

• Entry: FDA pathways and the regulatory realities a European company meets first.
• Price: US pricing and reimbursement — payers, PBMs and the logic that decides what you actually get.
• Win: the commercial and access strategy that turns approval into American revenue.

Who it’s for

European pharma and biotech leaders planning a US launch — and anyone who knows that in the US, as in Germany, authorized is not the same as paid.